Corbus Pharmaceuticals Holdings, Inc. (0SZI.L)
USD 4.92
(1.76%)
USD 4.92
(1.76%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 6.96 Million USD | -13.84% |
| 2022 | 8.08 Million USD | 410.51% |
| 2021 | 1.58 Million USD | 102.7% |
| 2020 | -58.59 Million USD | -162.73% |
| 2019 | -22.3 Million USD | 46.07% |
| 2018 | -41.35 Million USD | 33.52% |
| 2017 | -62.2 Million USD | -322.7% |
| 2016 | -14.71 Million USD | -20.86% |
| 2015 | -12.17 Million USD | -99.02% |
| 2014 | -6.11 Million USD | -1925.97% |
| 2013 | 335.05 Thousand USD | 61863.78% |
| 2012 | -542.48 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -9.17 Million USD | -416.44% |
| 2024 Q1 | 2.89 Million USD | -58.39% |
| 2023 Q1 | 17.51 Million USD | 116.54% |
| 2023 FY | 6.96 Million USD | -13.84% |
| 2023 Q4 | 6.96 Million USD | -39.97% |
| 2023 Q3 | 11.6 Million USD | -24.48% |
| 2023 Q2 | 15.36 Million USD | -12.23% |
| 2022 Q4 | 8.08 Million USD | -38.16% |
| 2022 Q3 | 13.07 Million USD | 39923.61% |
| 2022 Q2 | -32.83 Thousand USD | 99.89% |
| 2022 Q1 | -30.85 Million USD | -2047.85% |
| 2022 FY | 8.08 Million USD | 410.51% |
| 2021 FY | 1.58 Million USD | 102.7% |
| 2021 Q1 | -40.14 Million USD | 31.49% |
| 2021 Q3 | -11.21 Million USD | -12.2% |
| 2021 Q2 | -9.99 Million USD | 75.1% |
| 2021 Q4 | 1.58 Million USD | 114.13% |
| 2020 Q3 | -55.68 Million USD | -1.48% |
| 2020 Q1 | -37.58 Million USD | -68.51% |
| 2020 Q4 | -58.59 Million USD | -5.22% |
| 2020 FY | -58.59 Million USD | -162.73% |
| 2020 Q2 | -54.87 Million USD | -46.02% |
| 2019 FY | -22.3 Million USD | 46.07% |
| 2019 Q4 | -22.3 Million USD | 52.06% |
| 2019 Q3 | -46.52 Million USD | 28.9% |
| 2019 Q2 | -65.43 Million USD | 20.54% |
| 2019 Q1 | -82.35 Million USD | -99.14% |
| 2018 Q4 | -41.35 Million USD | 25.7% |
| 2018 Q3 | -55.65 Million USD | 13.83% |
| 2018 Q2 | -64.59 Million USD | 8.7% |
| 2018 Q1 | -70.74 Million USD | -13.73% |
| 2018 FY | -41.35 Million USD | 33.52% |
| 2017 FY | -62.2 Million USD | -322.7% |
| 2017 Q4 | -62.2 Million USD | -69.98% |
| 2017 Q1 | -48.76 Million USD | -231.4% |
| 2017 Q3 | -36.59 Million USD | 14.88% |
| 2017 Q2 | -42.99 Million USD | 11.85% |
| 2016 FY | -14.71 Million USD | -20.86% |
| 2016 Q2 | -22 Million USD | -129.31% |
| 2016 Q1 | -9.59 Million USD | 21.2% |
| 2016 Q4 | -14.71 Million USD | 22.15% |
| 2016 Q3 | -18.9 Million USD | 14.08% |
| 2015 Q2 | -9.24 Million USD | -88.68% |
| 2015 Q1 | -4.89 Million USD | 19.93% |
| 2015 Q4 | -12.17 Million USD | 7.57% |
| 2015 FY | -12.17 Million USD | -99.02% |
| 2015 Q3 | -13.17 Million USD | -42.52% |
| 2014 Q4 | -6.11 Million USD | 18.0% |
| 2014 Q2 | -7.86 Million USD | -1753.25% |
| 2014 Q1 | 475.77 Thousand USD | 42.0% |
| 2014 FY | -6.11 Million USD | -1925.97% |
| 2014 Q3 | -7.46 Million USD | 5.14% |
| 2013 FY | 335.05 Thousand USD | 61863.78% |
| 2013 Q1 | 542.48 USD | 0.0% |
| 2013 Q4 | 335.05 Thousand USD | 0.0% |
| 2012 FY | -542.48 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 106.768% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 122.321% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 96.482% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 78.146% |
| bluebird bio, Inc. | 108.57 Million USD | 93.582% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 177.286% |
| Imunon, Inc. | -4.69 Million USD | 248.28% |
| Editas Medicine, Inc. | -87.11 Million USD | 107.999% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 99.946% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 99.668% |
| Myriad Genetics, Inc. | 88.1 Million USD | 92.091% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 96.07% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 120.783% |
| Verastem, Inc. | -37.27 Million USD | 118.692% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 99.915% |
| Waters Corporation | 1.96 Billion USD | 99.645% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 99.974% |
| Biogen Inc. | 6.28 Billion USD | 99.889% |
| Nektar Therapeutics | 210.24 Million USD | 96.686% |
| Perrigo Company plc | 3.32 Billion USD | 99.79% |
| Dynavax Technologies Corporation | 106.63 Million USD | 93.465% |
| Illumina, Inc. | 1.21 Billion USD | 99.426% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 106.118% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 95.197% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 3.046% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 98.16% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 198.142% |
| Evolus, Inc. | 63.7 Million USD | 89.062% |
| Adicet Bio, Inc. | -142 Million USD | 104.907% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 118.933% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 125.712% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 98.481% |
| FibroGen, Inc. | 56.76 Million USD | 87.725% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 99.391% |
| OPKO Health, Inc. | 230.68 Million USD | 96.979% |
| Homology Medicines, Inc. | 18.43 Million USD | 62.206% |
| Geron Corporation | 14.76 Million USD | 52.794% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 99.56% |
| Exelixis, Inc. | -73.05 Million USD | 109.539% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 112.843% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 104.614% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 106.255% |
| Zoetis Inc. | 4.76 Billion USD | 99.854% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 103.487% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 169.19% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.073% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 147.818% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 99.339% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 99.28% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 105.146% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 99.495% |
| Blueprint Medicines Corporation | 702.83 Million USD | 99.009% |
| Insmed Incorporated | 721.62 Million USD | 99.034% |
| TG Therapeutics, Inc. | 17.86 Million USD | 60.989% |
| Incyte Corporation | -3.17 Billion USD | 100.219% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 99.09% |